drugset
drugset / Trial / NCT03436862

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

NCT03436862 ↗

Phase 2 Completed 37 enrolled SCRI Development Innovations, LLC Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase II single-arm open-label study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression.

Timeline

Start
2018-05-23
Primary completion
2022-05-05
Completion
2023-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 240 mg Intravenous

Indications

Hodgkins lymphoma